Cholesterol-Lowering Therapy - Evaluation of Clinical Trial Evidence

Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States.
This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations.
Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants.
Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence

highlights historical studies of dietary trials designed to reduce CHD

covers tests of HMG CoA reductase inhibitors for patients with and without CHD

illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking

explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors

reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol

and more!
Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.

List of contents

Cholesterol-Lowering Clinical Trials: A Historical Perspective
Scott M. Grundy
Scandinavian Simvastatin Survival Study (4S)
Terje R. Pedersen
The Cholesterol and Recurrent Events Trial (CARE): The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels
Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé, C. Morton Hawkins, Barry R. Davis, Jean L. Rouleau, Thomas G. Cole, and Eugene Braunwald
Lessons from the West of Scotland Coronary Prevention Study (WOSCOPS)
James Shepherd and Allan Gaw
Program on the Surgical Control of the Hyperlipidemias (POSCH) Trial: A Pivotal 25-Year Study
Henry Buchwald
The Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary Prevention of Acute Major Coronary Events in Women and Men with Average Cholesterol
Stephen Weis, Michael Clearfield, Lt. Col. John R. Downs, and Antonio M. Gotto, Jr.
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study: Clinical Implications for Cardiovascular Practice
Andrew M. Tonkin and David Hunt
Angiographic Results of Lipid-Lowering Trials: A Systematic Review and Meta-Analysis
Cheryl L. Holmes, Michael Schulzer, and G. B. John Mancini
Biochemical Correlates of Plaque Progression and Coronary Events
Melissa Ferraro-Borgida and David Waters
Lipid Therapy to Stabilize the Vulnerable Atherosclerotic Plaque: New Insights into the Prevention of Cardiovascular Events
B. Greg Brown and Xue-Qiao Zhao
Cholesterol-Lowering Trials with Carotid Ultrasonographic Outcomes
Robert P. Byington
Cholesterol Lowering Reduces Mortality: The Statins
David J. Gordon

About the author

Scott M. Grundy

Summary

Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States.
This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations.
Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants.
Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence

highlights historical studies of dietary trials designed to reduce CHD

covers tests of HMG CoA reductase inhibitors for patients with and without CHD

illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking

explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors

reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol

and more!
Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.

Product details

• Authors: Scott M. Grundy
• Assisted by: Scott M Grundy (Editor), Scott M. Grundy (Editor)
• Publisher: Taylor & Francis Ltd.
• Languages: English
• Product format: Paperback / Softback
• Released: 31.08.2019
• EAN: 9780367399320
• ISBN: 978-0-367-39932-0
• No. of pages: 352
• Subject: Natural sciences, medicine, IT, technology > Medicine > General